News
06-09-2011, 10:00 PM
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that full results from the NEO3-05 study, demonstrating Lymphoseek met all primary and secondary endpoints in intraoperative lymphatic mapping (ILM) procedures.
More... (http://www.news-medical.net/news/20110610/Neoprobes-Lymphoseek-Phase-3-trial-data-presented-at-SNM-annual-meeting.aspx)
More... (http://www.news-medical.net/news/20110610/Neoprobes-Lymphoseek-Phase-3-trial-data-presented-at-SNM-annual-meeting.aspx)